News & AnalysisAffinia Therapeutics locks in $60m Series AAffinia Therapeutics, a gene therapy company, has secured $60 million in Series A financing.ByIris Dorbian31 March 2020•1 min readJavaScript is required to read this article. Please enable it in your browser and reload the page.DealsHealthcareBriefs